AlzChem Group AG
XMUN:ACT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
AlzChem Group AG
XMUN:ACT
|
DE |
|
Thinksmart Ltd
LSE:TSL
|
AU |
|
Scully Royalty Ltd
F:MB01
|
HK |
|
B
|
Beijing North Star Co Ltd
XBER:BJ3
|
CN |
|
W
|
Waitr Holdings Inc
F:1OW0
|
US |
|
Saga PLC
F:65J
|
UK |
|
Tekcapital PLC
LSE:TEK
|
UK |
AlzChem Group AG
AlzChem Group AG is a German specialty chemicals company that makes high-purity chemical building blocks and finished specialty ingredients. Its products include chemicals used in pharmaceuticals, agriculture, animal nutrition, metallurgy, plastics, and other industrial processes. In simple terms, it sits in the middle of the chemical value chain: it turns basic raw materials into narrow-purpose chemicals that other manufacturers need. The company sells mainly to industrial customers rather than consumers. Some buyers use its products as ingredients in their own manufacturing, while others buy ready-made specialty compounds such as creatine, dicyandiamide, and other performance chemicals. AlzChem makes money by producing and selling these chemical products, often in technical grades or customer-specific forms, and by supplying recurring industrial demand for inputs that are hard to source elsewhere. What makes AlzChem different is its focus on a few specialized chemistry niches instead of broad commodity chemicals. It relies on deep process know-how, controlled production, and an integrated manufacturing setup that helps it make complex products consistently. That gives it a role as a supplier of essential niche inputs for customers that need reliable quality and stable formulations.
AlzChem Group AG is a German specialty chemicals company that makes high-purity chemical building blocks and finished specialty ingredients. Its products include chemicals used in pharmaceuticals, agriculture, animal nutrition, metallurgy, plastics, and other industrial processes. In simple terms, it sits in the middle of the chemical value chain: it turns basic raw materials into narrow-purpose chemicals that other manufacturers need.
The company sells mainly to industrial customers rather than consumers. Some buyers use its products as ingredients in their own manufacturing, while others buy ready-made specialty compounds such as creatine, dicyandiamide, and other performance chemicals. AlzChem makes money by producing and selling these chemical products, often in technical grades or customer-specific forms, and by supplying recurring industrial demand for inputs that are hard to source elsewhere.
What makes AlzChem different is its focus on a few specialized chemistry niches instead of broad commodity chemicals. It relies on deep process know-how, controlled production, and an integrated manufacturing setup that helps it make complex products consistently. That gives it a role as a supplier of essential niche inputs for customers that need reliable quality and stable formulations.
Strong half-year: AlzChem said first-half 2026 revenue rose 6% to almost EUR 304 million and EBITDA rose 14% to EUR 64.5 million, with margins improving to 21.2%.
Specialty Chemicals led: The Specialty Chemicals segment remained the main growth engine, helped by higher volumes, better pricing and strong demand in human nutrition, defense-related applications and custom manufacturing.
Guidance confirmed: Management kept full-year 2026 guidance unchanged at about EUR 600 million of sales and about EUR 126 million of EBITDA, while noting some Q3 sales were pulled forward into the first half.
Expansion on track: The company said major projects in Germany and the U.S. are progressing as planned, including the nitroguanidine expansion, a new guanidine facility and the U.S. site decision at Bushy Park, South Carolina.
Demand mixed: Basics & Intermediates remained weak in agriculture and under pressure from Asian competition, though steel showed early signs of stabilization and management expects improvement in the second half.
Balance sheet strengthened: AlzChem secured a EUR 100 million financing package, which management said supports its growth plans and leaves the company well positioned for future investment.
